scholarly article | Q13442814 |
P50 | author | Jean Wactawski-Wende | Q30001860 |
Sylvia Wassertheil-Smoller | Q30002263 | ||
Leon J. Thal | Q56839882 | ||
Rebecca D. Jackson | Q72504541 | ||
Judith K. Ockene | Q113389547 | ||
Sally A Shumaker | Q114424439 | ||
Stephen R. Rapp | Q124352318 | ||
P2093 | author name string | Susan L Hendrix | |
Robert B Wallace | |||
Claudine Legault | |||
Annlouise R Assaf | |||
Jane Morley Kotchen | |||
WHIMS Investigators | |||
Beverly N Jones | |||
P433 | issue | 20 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | dementia | Q83030 |
estrogen | Q277954 | ||
mild cognitive impairment | Q1472703 | ||
cognitive dysfunction | Q57859955 | ||
P304 | page(s) | 2651-2662 | |
P577 | publication date | 2003-05-01 | |
P1433 | published in | The Journal of the American Medical Association | Q1470970 |
P1476 | title | Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial | |
P478 | volume | 289 |
Q33825736 | 17α-estradiol attenuates neuron loss in ovariectomized Dtg AβPP/PS1 mice. |
Q56031121 | 17α-estradiol: a less-feminizing estrogen |
Q44832611 | 17β-Estradiol, but not estrone, increases the survival and activation of new neurons in the hippocampus in response to spatial memory in adult female rats. |
Q36323138 | 17β-estradiol and progesterone regulate expression of β-amyloid clearance factors in primary neuron cultures and female rat brain |
Q45049923 | 3beta-20beta-dihydroxy-5alpha-pregnane (UC1011) antagonism of the GABA potentiation and the learning impairment induced in rats by allopregnanolone |
Q57157080 | A Heartfelt Message, Estrogen Replacement Therapy: Use It or Lose It |
Q38846232 | A comparison of progestins within three classes: Differential effects on learning and memory in the aging surgically menopausal rat. |
Q34316221 | A component of Premarin® enhances multiple cognitive functions and influences nicotinic receptor expression |
Q36290901 | A conceptual model of cognitive deficits in chronic heart failure |
Q33745024 | A cross-sectional study of hormone treatment and hippocampal volume in postmenopausal women: evidence for a limited window of opportunity |
Q38023908 | A decade post WHI, menopausal hormone therapy comes full circle--need for independent commission |
Q35986045 | A lack of ovarian function increases neuroinflammation in aged mice |
Q92158594 | A long-term cyclic plus tonic regimen of 17β-estradiol improves the ability to handle a high spatial working memory load in ovariectomized middle-aged female rats |
Q35198034 | A mechanism emerges for the critical period hypothesis for estrogen treatment |
Q37070656 | A network model of genomic hormone interactions underlying dementia and its translational validation through serendipitous off-target effect |
Q33925274 | A new approach to understanding the molecular mechanisms through which estrogens affect cognition |
Q24792589 | A philosophical analysis of the evidence-based medicine debate |
Q35634150 | A pilot randomized, single-blind, placebo-controlled trial of traditional acupuncture for vasomotor symptoms and mechanistic pathways of menopause |
Q39364029 | A practical guide to the management of menopausal symptoms in breast cancer patients |
Q24657278 | A preliminary study of the safety, feasibility and cognitive efficacy of soy isoflavone supplements in older men and women |
Q36428962 | A review and update of mechanisms of estrogen in the hippocampus and amygdala for anxiety and depression behavior |
Q34250612 | A second chance for hormone replacement therapy? |
Q90263988 | Accelerated Ovarian Failure as a Unique Model to Study Peri-Menopause Influence on Alzheimer's Disease |
Q35850425 | Actions and interactions of estradiol and glucocorticoids in cognition and the brain: Implications for aging women. |
Q34099770 | Acute responses to estradiol replacement in the olfactory system of apoE-deficient and wild-type mice |
Q35322167 | Advances in the prevention of Alzheimer's disease and dementia |
Q55395274 | Age at menopause and lifetime cognition: Findings from a British birth cohort study. |
Q37623629 | Age-dependent Effects of 17β-estradiol on the dynamics of estrogen receptor β (ERβ) protein-protein interactions in the ventral hippocampus |
Q33757617 | Age-dependent regulation of obesity and Alzheimer-related outcomes by hormone therapy in female 3xTg-AD mice |
Q36721813 | Age-related inflammatory diseases: role of genetics and gender in the pathophysiology of Alzheimer's disease |
Q44943067 | Alendronate in the prevention of osteoporosis: 7-year follow-up |
Q44915973 | Alternatives to hormone replacement therapy for menopause: an epidemiological evaluation |
Q30357424 | Alzheimer 100--highlights in the history of Alzheimer research. |
Q38675107 | Alzheimer Disease: Scientific Breakthroughs and Translational Challenges |
Q37638708 | Alzheimer disease in post-menopausal women: Intervene in the critical window period |
Q22252311 | Alzheimer mechanisms and therapeutic strategies |
Q64163825 | Alzheimer's Disease: Progress in the Development of Anti-amyloid Disease-Modifying Therapies |
Q34039983 | Alzheimer's Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments |
Q36894385 | Alzheimer's disease and mild cognitive impairment |
Q36946824 | Alzheimer's disease and other neurological disorders |
Q39629610 | Alzheimer's disease therapeutic trials: EU/US Task Force report on recruitment, retention, and methodology |
Q30620862 | Alzheimer's disease, dementia, mild cognitive impairment and the menopause: a 'window of opportunity'? |
Q57074482 | Alzheimer's disease, estrogens, and clinical trials: a case study in drug development for complex disorders |
Q38871979 | Alzheimer's disease, menopause and the impact of the estrogenic environment |
Q35687044 | Alzheimer's disease: pathological mechanisms and recent insights |
Q37315515 | Alzheimer's disease: review of hormone therapy trials and implications for treatment and prevention after menopause |
Q64060113 | Alzheimer's disease: risk factors and potentially protective measures |
Q33773031 | Alzheimer's prevention initiative: a proposal to evaluate presymptomatic treatments as quickly as possible |
Q35987458 | Ambient air pollution and neurotoxicity on brain structure: Evidence from women's health initiative memory study |
Q46129248 | An omnibus test for several hazard alternatives in prevention randomized controlled clinical trials |
Q37084906 | An update on the cognitive impact of clinically-used hormone therapies in the female rat: models, mazes, and mechanisms |
Q33896147 | An update on the diagnosis and management of dementing conditions |
Q37576090 | An update on treatment and prevention strategies for Alzheimer's disease |
Q35871132 | Androgen replacement therapy: present and future |
Q47332942 | Anti-aging medicine and research: a realm of conflict and profound societal implications |
Q42785187 | Anti-inflammatory drugs and Alzheimer's disease |
Q34066474 | Antioxidant therapy in Alzheimer's disease: theory and practice |
Q38398327 | Are there cognitive and neurobehavioural correlates of hormonal neuroprotection for women after TBI? |
Q35237981 | Ascertaining dementia-related outcomes for deceased or proxy-dependent participants: an overview of the Women's Health Initiative Memory Study supplemental case ascertainment protocol |
Q36666859 | Assessing and treating forgetfulness and cognitive problems in adults with HIV |
Q37015181 | Assessment of estradiol influence on spatial tasks and hippocampal CA1 spines: evidence that the duration of hormone deprivation after ovariectomy compromises 17beta-estradiol effectiveness in altering CA1 spines |
Q90619967 | Association Between Hormone-Modulating Breast Cancer Therapies and Incidence of Neurodegenerative Outcomes for Women With Breast Cancer |
Q38392550 | Association of bilateral oophorectomy with cognitive function in healthy, postmenopausal women |
Q50986104 | Attitudes of women who are currently using or recently stopped estrogen replacement therapy with or without progestins: results of the AWARE survey. |
Q37262126 | Behavioral consequences of ovarian atrophy and estrogen replacement in the APPswe mouse |
Q50783742 | Benchmarks for designing two-stage studies using modified mini-mental state examinations: experience from the Women's Health Initiative Memory Study. |
Q37483121 | Benefits of Hormone Therapy Estrogens Depend on Estrogen Type: 17β-Estradiol and Conjugated Equine Estrogens Have Differential Effects on Cognitive, Anxiety-Like, and Depressive-Like Behaviors and Increase Tryptophan Hydroxylase-2 mRNA Levels in Dor |
Q35072737 | Benzothiophene Selective Estrogen Receptor Modulators Provide Neuroprotection by a novel GPR30-dependent Mechanism |
Q24643351 | Bioidentical hormones for menopausal hormone therapy: variation on a theme |
Q91984204 | Blood pressure variability and brain morphology in elderly women without cardiovascular disease |
Q33742116 | Bone density and brain atrophy in early Alzheimer's disease |
Q35539109 | Bone mineral density in adolescent and young adult women on injectable or oral contraception |
Q34563775 | Bone protection by estrens occurs through non-tissue-selective activation of the androgen receptor |
Q34244907 | Brain estrogen deficiency accelerates Abeta plaque formation in an Alzheimer's disease animal model |
Q34091893 | Brain levels of sex steroid hormones in men and women during normal aging and in Alzheimer's disease |
Q37413116 | Brain volumes, cognitive impairment, and conjugated equine estrogens |
Q36349176 | Brain-derived neurotrophic factor Val(66)Met genotype and ovarian steroids interactively modulate working memory-related hippocampal function in women: a multimodal neuroimaging study |
Q36106017 | Building a better hormone therapy? How understanding the rapid effects of sex steroid hormones could lead to new therapeutics for age-related memory decline. |
Q35198156 | C terminus of Hsc70-interacting protein (CHIP)-mediated degradation of hippocampal estrogen receptor-alpha and the critical period hypothesis of estrogen neuroprotection |
Q36843004 | CAP--advancing the evaluation of preclinical Alzheimer disease treatments |
Q44640274 | Calcium Channel Blockers (Felodipine) and Pediatric Essential Hypertension |
Q36463375 | Calcium and vitamin D supplementation and cognitive impairment in the women's health initiative |
Q37457697 | Cardiovascular disease and cognitive decline in postmenopausal women: results from the Women's Health Initiative Memory Study |
Q36892860 | Care of the menopausal patient: a nurse practitioner's view |
Q81163509 | Changes in health-related behaviours following BRCA 1/2 genetic testing: the case of hormone replacement therapy |
Q35866374 | Changing concepts: Menopausal hormone therapy and breast cancer |
Q34361818 | Characteristics of hormone therapy, cognitive function, and dementia: the prospective 3C Study. |
Q99573908 | Characterizing the effects of tonic 17β-estradiol administration on spatial learning and memory in the follicle-deplete middle-aged female rat |
Q34303501 | Characterizing the preclinical stages of Alzheimer's disease and the prospect of presymptomatic intervention |
Q36107446 | Chemocentric informatics approach to drug discovery: identification and experimental validation of selective estrogen receptor modulators as ligands of 5-hydroxytryptamine-6 receptors and as potential cognition enhancers |
Q43438290 | Chronic administration of tibolone modulates anxiety-like behavior and enhances cognitive performance in ovariectomized rats |
Q34978792 | Chronic treatment with the nitric oxide synthase inhibitor, L-NAME, attenuates estradiol-mediated improvement of learning and memory in ovariectomized rats |
Q36072505 | Clinical appraisal of the Women's Health Initiative |
Q47942644 | Clinical outcomes in older surgical patients with mild cognitive impairment. |
Q31155412 | Clinical practice with anti-dementia drugs: A revised (third) consensus statement from the British Association for Psychopharmacology |
Q37810697 | Clinical practice with anti-dementia drugs: a revised (second) consensus statement from the British Association for Psychopharmacology |
Q57122063 | Clinical predictors of older driver performance on a standardized road test |
Q36854928 | Clinically relevant hormone treatments fail to induce spinogenesis in prefrontal cortex of aged female rhesus monkeys |
Q35757574 | Cognition, mood disorders, and sex hormones |
Q58551763 | Cognitive Changes with Reproductive Aging, Perimenopause, and Menopause |
Q46153359 | Cognitive Function and Changes in Cognitive Function as Predictors of Incident Cardiovascular Disease: The Women's Health Initiative Memory Study |
Q33761005 | Cognitive benefits of hormone therapy: cardiovascular factors and healthy-user bias |
Q37088621 | Cognitive changes after menopause: influence of estrogen |
Q36919235 | Cognitive decline and dementia in the oldest-old |
Q34070875 | Cognitive deficits and health-related quality of life in chronic heart failure |
Q34070832 | Cognitive deficits in chronic heart failure |
Q36443732 | Cognitive dysfunction with aging and the role of inflammation |
Q38551397 | Cognitive effects of endocrine therapy for breast cancer: keep calm and carry on? |
Q45960420 | Cognitive effects of short-term use of raloxifene: a randomized clinical trial. |
Q36539736 | Cognitive performance in healthy women during induced hypogonadism and ovarian steroid addback |
Q92656269 | Cognitive resilience among APOE ε4 carriers in the oldest old |
Q48305628 | Cognitive symptoms during the menopausal transition and early postmenopause |
Q37207741 | Cognitive-impairing effects of medroxyprogesterone acetate in the rat: independent and interactive effects across time |
Q47711481 | Combination Therapy for Multi-Target Manipulation of Secondary Brain Injury Mechanisms |
Q35152376 | Combination hormone replacement therapy and dementia |
Q35691705 | Combination of Micronutrients for Bone (COMB) Study: bone density after micronutrient intervention |
Q35936864 | Combination therapy in Alzheimer's disease: a review of current evidence |
Q24186056 | Comparison of central adjudication of outcomes and onsite outcome assessment on treatment effect estimates |
Q51968280 | Comparison of the design differences between the Ginkgo Evaluation of Memory study and the GuidAge study. |
Q24682645 | Comparison of the in vitro estrogenic activities of compounds from hops (Humulus lupulus) and red clover (Trifolium pratense) |
Q37650744 | Complexities of oestrogen in stroke |
Q34974644 | Concurrent and longitudinal relationships between cognitive activity, cognitive performance, and brain volume in older adult women |
Q33600226 | Consortium to Establish a Registry for Alzheimer's Disease (CERAD): the first twenty years |
Q33874451 | Continuous and cyclic progesterone differentially interact with estradiol in the regulation of Alzheimer-like pathology in female 3xTransgenic-Alzheimer's disease mice |
Q36558503 | Continuous transdermal nitroglycerin therapy for menopausal hot flashes: a single-arm, dose-escalation trial |
Q34185639 | Continuous versus cyclic progesterone exposure differentially regulates hippocampal gene expression and functional profiles |
Q37642394 | Continuously delivered ovarian steroids do not alter dendritic spine density or morphology in macaque dorsolateral prefrontal cortical neurons |
Q47217248 | Contrasting effects of individual versus combined estrogen and progestogen regimens as working memory load increases in middle-aged ovariectomized rats: one plus one does not equal two. |
Q55517857 | Correction for retest effects across repeated measures of cognitive functioning: a longitudinal cohort study of postoperative delirium. |
Q30634935 | Critical window hypothesis of hormone therapy and cognition: a scientific update on clinical studies |
Q35544962 | Current Treatment for Alzheimer Disease and Future Prospects |
Q36444574 | Current advances in the treatment of Alzheimer's disease: focused on considerations targeting Aβ and tau. |
Q37360292 | Current concepts in Alzheimer's disease: a multidisciplinary review |
Q35618929 | Current concepts in the prevention of Alzheimer's disease |
Q36575001 | Current treatment of mild cognitive impairment and Alzheimer's disease |
Q42170272 | Cyclic estrogen replacement improves cognitive function in aged ovariectomized rhesus monkeys. |
Q33371496 | Data analysis methods and the reliability of analytic epidemiologic research |
Q36993348 | Decreased oxidant profile and increased antioxidant capacity in naturally postmenopausal women. |
Q38778638 | Defeating Alzheimer's disease and other dementias: a priority for European science and society |
Q33206399 | Dementia / Alzheimer's Disease |
Q33924014 | Dementia and cognitive impairment: epidemiology, diagnosis, and treatment |
Q37263684 | Dementia prevention: methodological explanations for inconsistent results |
Q36787352 | Dementia syndromes: evaluation and treatment |
Q57725293 | Dementia: new projections and time for an updated response |
Q48930833 | Depressive symptoms and incidence of mild cognitive impairment and probable dementia in elderly women: the Women's Health Initiative Memory Study |
Q35028141 | Depressive symptoms, brain volumes and subclinical cerebrovascular disease in postmenopausal women: the Women's Health Initiative MRI Study |
Q30352600 | Description of an Audio-Based Paced Respiration Intervention for Vasomotor Symptoms. |
Q37171151 | Developing new treatments for Alzheimer's disease: the who, what, when, and how of biomarker-guided therapies |
Q35850280 | Development of the CHARIOT Research Register for the Prevention of Alzheimer's Dementia and Other Late Onset Neurodegenerative Diseases |
Q30374316 | Device-guided slow-paced respiration for menopausal hot flushes: a randomized controlled trial. |
Q89723747 | Devising a new dialogue for nutrition science: how life course perspective, U-shaped thinking, whole organism thinking, and language precision contribute to our understanding of biological heterogeneity and forge a fresh advance toward precision med |
Q36585264 | Diagnosis and treatment of dementia: 3. Mild cognitive impairment and cognitive impairment without dementia |
Q34089759 | Diagnostic Tests for Alzheimer's Disease: Rationale, Methodology, and Challenges |
Q22252600 | Diet and Alzheimer’s disease |
Q43196397 | Diet and the risk for Alzheimer's disease |
Q45841349 | Differences Between Gynecologists and Primary Care Physicians in Hormone Therapy Prescribing: Why They Matter |
Q34494238 | Differences in regional brain metabolism associated with specific formulations of hormone therapy in postmenopausal women at risk for AD. |
Q31055402 | Differential aging of the brain: patterns, cognitive correlates and modifiers |
Q37665855 | Differential contribution of APP metabolites to early cognitive deficits in a TgCRND8 mouse model of Alzheimer's disease |
Q35112139 | Differential effects of dopamine receptor D1-type and D2-type antagonists and phase of the estrous cycle on social learning of food preferences, feeding, and social interactions in mice. |
Q46899482 | Differential effects of estrogen receptor alpha and beta specific agonists on social learning of food preferences in female mice |
Q37143947 | Differential effects on visual and spatial recognition memory of a novel hormone therapy regimen of estrogen alone or combined with progesterone in older surgically menopausal monkeys |
Q28577277 | Differential responses of progesterone receptor membrane component-1 (Pgrmc1) and the classical progesterone receptor (Pgr) to 17β-estradiol and progesterone in hippocampal subregions that support synaptic remodeling and neurogenesis |
Q36656437 | Disease-modifying therapies in Alzheimer's disease: how far have we come? |
Q36441754 | Dismembering the ethical physician |
Q35812383 | Distinct cognitive effects of estrogen and progesterone in menopausal women |
Q35918601 | Divergent impact of progesterone and medroxyprogesterone acetate (Provera) on nuclear mitogen-activated protein kinase signaling |
Q37100148 | Does lifetime exposure to hormones predict pretreatment cognitive function in women before adjuvant therapy for breast cancer? |
Q49841666 | Does phytoestrogen supplementation improve cognition in humans? A systematic review |
Q46440950 | Does raloxifene treatment influence back pain and disability among postmenopausal women with osteoporosis? |
Q37157784 | Dose-dependent effects of post-training estradiol plus progesterone treatment on object memory consolidation and hippocampal extracellular signal-regulated kinase activation in young ovariectomized mice |
Q33915170 | Down-regulation of serum gonadotropins is as effective as estrogen replacement at improving menopause-associated cognitive deficits |
Q35827072 | Dramatic change in prescribing of hormone replacement therapy in The Netherlands after publication of the Million Women Study: a follow-up study |
Q36826910 | Driving with Mild Cognitive Impairment or Dementia: Cognitive Test Performance and Proxy Report of Daily Life Function in Older Women |
Q21091197 | Drug and cell type-specific regulation of genes with different classes of estrogen receptor beta-selective agonists |
Q34320568 | Duration of estrogen deprivation, not chronological age, prevents estrogen's ability to enhance hippocampal synaptic physiology |
Q36063538 | Dysregulation of the hypothalamic-pituitary-gonadal axis with menopause and andropause promotes neurodegenerative senescence |
Q35498087 | Early initiation of hormone therapy in menopausal women is associated with increased hippocampal and posterior cingulate cholinergic activity |
Q33981652 | Early menopausal hormone use influences brain regions used for visual working memory |
Q50738168 | Effect of estrogen and testosterone replacement therapy on cognitive fatigue. |
Q36123416 | Effect of estrogen-serotonin interactions on mood and cognition |
Q50437088 | Effect of tibolone on audiologic functions in menopausal women |
Q36684570 | Effects of Hormone Therapy on Brain Volumes Changes of Postmenopausal Women Revealed by Optimally-Discriminative Voxel-Based Morphometry |
Q28547748 | Effects of Hormone Therapy on Cognition and Mood in Recently Postmenopausal Women: Findings from the Randomized, Controlled KEEPS-Cognitive and Affective Study |
Q37482736 | Effects of aromatase inhibition on bone mineral density and bone turnover in older men with low testosterone levels. |
Q37417437 | Effects of conjugated equine estrogens on cognition and affect in postmenopausal women with prior hysterectomy |
Q42459286 | Effects of estrogen replacement therapy on cholinergic basal forebrain neurons and cortical cholinergic innervation in young and aged ovariectomized rhesus monkeys |
Q26865143 | Effects of hormone therapy on cognition and mood |
Q58726869 | Effects of isoflavones on breast tissue and the thyroid hormone system in humans: a comprehensive safety evaluation |
Q31112372 | Effects of long-term testosterone administration on cognition in older men with low or low-to-normal testosterone concentrations: a prespecified secondary analysis of data from the randomised, double-blind, placebo-controlled TEAAM trial |
Q33889042 | Effects of long-term treatment with 17 beta-estradiol and medroxyprogesterone acetate on water maze performance in middle aged female rats |
Q36066982 | Effects of long-term treatment with estrogen and medroxyprogesterone acetate on synapse number in the medial prefrontal cortex of aged female rats |
Q48100705 | Effects of long-term, low-dose sex hormone replacement therapy on hippocampus and cognition of postmenopausal women of different apoE genotypes. |
Q44898010 | Effects of raloxifene, one of the selective estrogen receptor modulators, on pituitary-ovary axis and prolactin in postmenopausal women. |
Q41442478 | Effects of synaptic plasticity regulated by 17beta-estradiol on learning and memory in rats with Alzheimer's disease |
Q50921356 | Effects of testosterone on cognition and mood in male patients with mild Alzheimer's disease and elderly men. |
Q43286294 | Effects of the LHRH antagonist Cetrorelix on affective and cognitive functions in rats |
Q46046661 | Effects of the LHRH antagonist Cetrorelix on the brain function in mice |
Q36739764 | Effects of two estradiol regimens on anxiety and depressive behaviors and trophic effects in peripheral tissues in a rodent model |
Q37439245 | Effects of two years of conjugated equine estrogens on cholinergic neurons in young and middle-aged ovariectomized monkeys |
Q46864419 | Efficacy and safety of 17alpha-hydroxyprogesterone caproate in hormone replacement therapy |
Q35593989 | Efficacy and safety of long-term bisphosphonates in postmenopausal osteoporosis |
Q28295716 | Emerging drugs for sarcopenia: age-related muscle wasting |
Q36492347 | Emerging therapeutics for Alzheimer's disease |
Q35618922 | Emerging therapeutics for Alzheimer's disease: an avenue of hope |
Q38067477 | Endocrinology of menopause. |
Q37141534 | Endpoints for trials in Alzheimer's disease: a European task force consensus |
Q35876333 | Enhanced neuroactivation during verbal memory processing in postmenopausal women receiving short-term hormone therapy |
Q35915312 | Enrollment in a brain magnetic resonance study: results from the Women's Health Initiative Memory Study Magnetic Resonance Imaging Study (WHIMS-MRI). |
Q34804413 | Environmental enrichment reduces the mnemonic and neural benefits of estrogen |
Q36546512 | Epidemiological and clinical trials evidence about a preventive role for statins in Alzheimer's disease |
Q37947688 | Epidemiological findings of vascular risk factors in Alzheimer's disease: implications for therapeutic and preventive intervention |
Q40069328 | Epidemiology of estrogen and dementia in women with Down syndrome |
Q37195414 | Escitalopram reduces hot flashes in nondepressed menopausal women: A pilot study |
Q45270702 | Estradiol and cognition during androgen deprivation in men with prostate carcinoma |
Q35054370 | Estradiol and cognitive function: past, present and future |
Q37484251 | Estradiol and the relationship between dendritic spines, NR2B containing NMDA receptors, and the magnitude of long-term potentiation at hippocampal CA3-CA1 synapses |
Q40626859 | Estradiol binding to maxi-K channels induces their down-regulation via proteasomal degradation |
Q42517451 | Estradiol enhances long term potentiation in hippocampal slices from aged apoE4-TR mice |
Q48330937 | Estradiol enhances neurogenesis following ischemic stroke through estrogen receptors alpha and beta |
Q37324561 | Estradiol enhances sociosexual behavior and can have proliferative effects in ovariectomized rats |
Q36732302 | Estradiol interacts with the cholinergic system to affect verbal memory in postmenopausal women: evidence for the critical period hypothesis |
Q33875866 | Estradiol replacement extends the window of opportunity for hippocampal function |
Q36748785 | Estradiol to aged female or male mice improves learning in inhibitory avoidance and water maze tasks |
Q34482256 | Estrogen Effects on Cognitive and Synaptic Health Over the Lifecourse |
Q37136803 | Estrogen Receptor {alpha} Enhances the Rate of Oxidative DNA Damage by Targeting an Equine Estrogen Catechol Metabolite to the Nucleus |
Q34481021 | Estrogen action in mood and neurodegenerative disorders: estrogenic compounds with selective properties-the next generation of therapeutics |
Q42491540 | Estrogen alters spine number and morphology in prefrontal cortex of aged female rhesus monkeys. |
Q33649188 | Estrogen and Progesterone Replacement Therapy Prevent Methamphetamine-Induced Synaptic Plasticity Impairment in Ovariectomized Rats |
Q27025613 | Estrogen and cognitive functioning in women: lessons we have learned |
Q48192809 | Estrogen and dementia: it's a long way from the rat to the randomized clinical trial |
Q33644111 | Estrogen and hippocampal plasticity in rodent models |
Q36039975 | Estrogen and memory in women: how can we reconcile the findings? |
Q46207103 | Estrogen and performance in recognition memory for olfactory and visual stimuli in females diagnosed with Alzheimer's disease |
Q33924621 | Estrogen and the prefrontal cortex: towards a new understanding of estrogen's effects on executive functions in the menopause transition |
Q34784469 | Estrogen anti-inflammatory activity in brain: a therapeutic opportunity for menopause and neurodegenerative diseases |
Q33595388 | Estrogen attenuates ischemic oxidative damage via an estrogen receptor alpha-mediated inhibition of NADPH oxidase activation |
Q44697391 | Estrogen decreases zinc transporter 3 expression and synaptic vesicle zinc levels in mouse brain |
Q35785178 | Estrogen neuroprotection and the critical period hypothesis |
Q48488958 | Estrogen receptor alpha and APOEepsilon4 polymorphisms interact to increase risk for sporadic AD in Italian females |
Q53270093 | Estrogen receptor beta gene variants are associated with increased risk of Alzheimer's disease in women. |
Q36322578 | Estrogen receptor β in Alzheimer's disease: From mechanisms to therapeutics |
Q36876459 | Estrogen receptor-mediated neuroprotection: The role of the Alzheimer's disease-related gene seladin-1 |
Q37241063 | Estrogen regulation of Dkk1 and Wnt/β-Catenin signaling in neurodegenerative disease |
Q34360055 | Estrogen regulation of glucose metabolism and mitochondrial function: therapeutic implications for prevention of Alzheimer's disease |
Q37675866 | Estrogen regulation of mitochondrial bioenergetics: implications for prevention of Alzheimer's disease |
Q46058009 | Estrogen replacement therapy, Alzheimer's disease, and mild cognitive impairment |
Q21284766 | Estrogen signaling and the aging brain: context-dependent considerations for postmenopausal hormone therapy |
Q92042117 | Estrogen sulfotransferase in the metabolism of estrogenic drugs and in the pathogenesis of diseases |
Q36677805 | Estrogen synthesis and signaling pathways during aging: from periphery to brain |
Q48335998 | Estrogen therapy and brain muscarinic receptor density in healthy females: a SPET study |
Q33779694 | Estrogen therapy and cognition: a review of the cholinergic hypothesis |
Q46947447 | Estrogen treatment effects on anticholinergic-induced cognitive dysfunction in normal postmenopausal women |
Q50720565 | Estrogen treatment effects on cognition, memory and mood in male-to-female transsexuals. |
Q99345086 | Estrogen, brain structure, and cognition in postmenopausal women |
Q34585797 | Estrogen, cognition and female ageing |
Q36621171 | Estrogen, menopause, and the aging brain: how basic neuroscience can inform hormone therapy in women. |
Q24805637 | Estrogen, progesterone and epithelial ovarian cancer |
Q35690176 | Estrogen-BDNF interactions: implications for neurodegenerative diseases. |
Q33677902 | Estrogen-Related Factors in the Frontal Lobe of Alzheimer's Disease Patients and Importance of Body Mass Index |
Q26799402 | Estrogen-cholinergic interactions: Implications for cognitive aging |
Q53266049 | Estrogen-metabolizing gene COMT polymorphism synergistic APOE epsilon4 allele increases the risk of Alzheimer disease. |
Q33623924 | Estrogen: a master regulator of bioenergetic systems in the brain and body |
Q28079898 | Estrogenic Endocrine Disrupting Chemicals Influencing NRF1 Regulated Gene Networks in the Development of Complex Human Brain Diseases |
Q37147787 | Estrogens and age-related memory decline in rodents: what have we learned and where do we go from here? |
Q34483748 | Estrogens and cognition: Friends or foes?: An evaluation of the opposing effects of estrogens on learning and memory |
Q36980880 | Estrogens and progesterone as neuroprotectants: what animal models teach us |
Q38739583 | Estrogens as neuroprotectants: Estrogenic actions in the context of cognitive aging and brain injury |
Q83753613 | Estrogens need insulin-like growth factor I cooperation to exert their neuroprotective effects in post-menopausal women |
Q36931711 | Estrogens, episodic memory, and Alzheimer's disease: a critical update |
Q34269755 | Estrogens, estrogen receptors, and female cognitive aging: the impact of timing |
Q26771644 | Estrogens, inflammation and cognition |
Q24612411 | European guidance for the diagnosis and management of osteoporosis in postmenopausal women |
Q37037296 | European guidance for the diagnosis and management of osteoporosis in postmenopausal women |
Q57465255 | European guidance for the diagnosis and management of osteoporosis in postmenopausal women |
Q38814359 | Evaluating the Role of Hormone Therapy in Postmenopausal Women with Alzheimer's Disease |
Q37007979 | Evaluation of estrogenic activity of licorice species in comparison with hops used in botanicals for menopausal symptoms |
Q80443430 | Evidence-based medicine and hormone replacement therapy |
Q37724078 | Evolution of Quantitative Measures in NMR: Quantum Mechanical qHNMR Advances Chemical Standardization of a Red Clover (Trifolium pratense) Extract. |
Q35615125 | Evolutionary rather than revolutionary progress in dementia |
Q50600187 | Executive functions in men and postmenopausal women. |
Q35682935 | Exercise and estrogen or estrogen alternatives (phytoestrogens, bisphosphonates)for preservation of bone mineral in postmenopausal women |
Q33357034 | Experiences of a long-term randomized controlled prevention trial in a maiden environment: Estonian Postmenopausal Hormone Therapy trial |
Q49586649 | FSH to estradiol ratio can be used as screening method for mild cognitive impairment in postmenopausal women |
Q36901959 | Factors influencing the cognitive and neural effects of hormone treatment during aging in a rodent model |
Q37090625 | Familial Alzheimer disease in Latinos: interaction between APOE, stroke, and estrogen replacement |
Q57301587 | Female Sex and Alzheimer's Risk: The Menopause Connection |
Q33756791 | Female reproductive factors, menopausal hormone use, and Parkinson's disease |
Q35034379 | Folate, vitamin B-6, and vitamin B-12 intake and mild cognitive impairment and probable dementia in the Women's Health Initiative Memory Study. |
Q37324566 | Frontiers proposal. National Institute on Aging "bench to bedside: estrogen as a case study". |
Q37605837 | GABA+ levels in postmenopausal women with mild-to-moderate depression: A preliminary study |
Q92543481 | GABA-A receptor modulating steroids in acute and chronic stress; relevance for cognition and dementia? |
Q34612871 | GPR30 is positioned to mediate estrogen effects on basal forebrain cholinergic neurons and cognitive performance |
Q35534146 | Galanthamine plus estradiol treatment enhances cognitive performance in aged ovariectomized rats |
Q26828629 | Gaps in menopause knowledge |
Q92542344 | Gender Difference in the Effects of Outdoor Air Pollution on Cognitive Function Among Elderly in Korea |
Q38225583 | Gender and cataract--the role of estrogen |
Q48382481 | Gender dependent APP processing in a transgenic mouse model of Alzheimer's disease |
Q36914115 | Gender differences in dementia risk factors |
Q36146996 | Gender, sex steroid hormones, and Alzheimer's disease. |
Q33427814 | Gender- and age-dependent gamma-secretase activity in mouse brain and its implication in sporadic Alzheimer disease |
Q42363857 | Genetic Analysis of Mitochondrial Ribosomal Proteins and Cognitive Aging in Postmenopausal Women |
Q37795699 | Genetic variability in estrogen disposition: Potential clinical implications for neuropsychiatric disorders |
Q40822236 | Genetically predicted 17beta-estradiol, cognitive function and depressive symptoms in women: A Mendelian randomization in the Guangzhou Biobank Cohort Study. |
Q36248069 | Genistein protects against Aβ25-35 induced apoptosis of PC12 cells through JNK signaling and modulation of Bcl-2 family messengers |
Q37028001 | Global cognitive function before, surrounding, and after ischemic stroke: the role of risk and protective factors varies with time among ischemic stroke survivors |
Q36909207 | Gonadal hormones and cognitive aging: a midlife perspective |
Q34673793 | Greater endogenous estrogen exposure is associated with longer telomeres in postmenopausal women at risk for cognitive decline |
Q22306361 | Guidelines for the Prevention of Stroke in Women: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association |
Q36408852 | Guidelines for the treatment of Alzheimer's disease from the Italian Association of Psychogeriatrics |
Q35539421 | HRT: Decide Based on the Evidence |
Q35563932 | HT and CVD prevention. from myth to reality |
Q50431361 | Hearing levels in menopausal women and the effect of tibolone on audiological functions. |
Q26740203 | Herbal Medicine for Hot Flushes Induced by Endocrine Therapy in Women with Breast Cancer: A Systematic Review and Meta-Analysis |
Q35787891 | High levels of estrogen enhance associative memory formation in ovariectomized females |
Q37567503 | Higher RBC EPA + DHA corresponds with larger total brain and hippocampal volumes: WHIMS-MRI study |
Q36755714 | Higher levels of estradiol replacement correlate with better spatial memory in surgically menopausal young and middle-aged rats |
Q34680911 | Hormonal influences on cognition and risk for Alzheimer's disease |
Q37029421 | Hormonal treatment, mild cognitive impairment and Alzheimer's disease |
Q57466987 | Hormone Replacement Therapy: Would it be Possible to Replicate a Functional Ovary? |
Q37115589 | Hormone effects on fMRI and cognitive measures of encoding: importance of hormone preparation |
Q35884815 | Hormone replacement therapy and risk for neurodegenerative diseases. |
Q24242542 | Hormone replacement therapy for cognitive function in postmenopausal women |
Q33554786 | Hormone replacement therapy for the primary prevention of chronic diseases: recommendation statement from the Canadian Task Force on Preventive Health Care |
Q35622642 | Hormone replacement therapy in climacteric and aging brain |
Q36668526 | Hormone replacement therapy in menopausal women: Past problems and future possibilities |
Q35966781 | Hormone replacement therapy in women with spinal cord injury - a survey with literature review |
Q24241789 | Hormone replacement therapy to maintain cognitive function in women with dementia |
Q36475295 | Hormone therapy and Alzheimer disease dementia: new findings from the Cache County Study. |
Q35680612 | Hormone therapy and Alzheimer's disease: benefit or harm? |
Q37381044 | Hormone therapy and cognitive function |
Q36051186 | Hormone therapy and risk for dementia: where do we go from here? |
Q37713006 | Hormone therapy at early post-menopause increases cognitive control-related prefrontal activity |
Q24202201 | Hormone therapy for sexual function in perimenopausal and postmenopausal women |
Q36459544 | Hormone therapy in the WHI era. |
Q36887336 | Hormone therapy, dementia, and cognition: the Women's Health Initiative 10 years on. |
Q38975101 | Hormone-replacement therapy: current thinking |
Q37165598 | Hormones and dementia - a comparative study of hormonal impairment in post-menopausal women, with and without dementia |
Q36362593 | Hormones and menopause: pro. |
Q35631823 | Human cholinergic basal forebrain: chemoanatomy and neurologic dysfunction. |
Q37036997 | Human chorionic gonadotropin (a luteinizing hormone homologue) decreases spatial memory and increases brain amyloid-beta levels in female rats. |
Q35876440 | Hypertension and dementia: does blood pressure control favorably affect cognition? |
Q36492399 | Hypertension, Dietary Sodium, and Cognitive Decline: Results From the Women's Health Initiative Memory Study |
Q36528233 | Hypothalamic-pituitary-gonadal axis homeostasis predicts longevity |
Q37594833 | Identification of a predictive biomarker for the beneficial effect of keishibukuryogan, a kampo (Japanese traditional) medicine, on patients with climacteric syndrome. |
Q34516562 | Identifying botanical mechanisms of action |
Q46375945 | Identifying target regions for vigilance improvement under hormone replacement therapy in postmenopausal syndrome patients by means of electroencephalographic tomography (LORETA). |
Q36311674 | Impact of Type 2 Diabetes and Postmenopausal Hormone Therapy on Incidence of Cognitive Impairment in Older Women |
Q50849905 | Impact of a premature menopause on cognitive function in later life. |
Q33827647 | Impact of atomoxetine on subjective attention and memory difficulties in perimenopausal and postmenopausal women |
Q35774584 | Impact of combined estradiol and norethindrone therapy on visuospatial working memory assessed by functional magnetic resonance imaging |
Q35771516 | Impact of estrogen therapy on Alzheimer's disease: a fork in the road? |
Q36372962 | Impact of risk-reducing salpingo-oophorectomy in premenopausal women |
Q52343348 | Impact of sex steroids and reproductive stage on sleep-dependent memory consolidation in women. |
Q37764494 | Impact of the hypothalamic-pituitary-adrenal/gonadal axes on trajectory of age-related cognitive decline |
Q37125488 | Impaired cognition and attention in adults: pharmacological management strategies |
Q46526541 | Implications of statin adverse effects in the elderly |
Q34316296 | Increased memory load-related frontal activation after estradiol treatment in postmenopausal women |
Q57816569 | Inflammation: Bridging Age, Menopause and APOEε4 Genotype to Alzheimer's Disease |
Q37812784 | Inhibition of estrogen actions in human gynecological malignancies: New aspects of endocrine therapy for endometrial cancer and ovarian cancer |
Q28482218 | Insulinotropic effect of the non-steroidal compound STX in pancreatic β-cells |
Q28394967 | Interactions between inflammation, sex steroids, and Alzheimer's disease risk factors |
Q35194607 | Interactive effects of age and estrogen on cortical neurons: implications for cognitive aging |
Q34206248 | Interactive effects of estrogen and serotonin on brain activation during working memory and affective processing in menopausal women |
Q37436161 | Intraindividual variability in domain-specific cognition and risk of mild cognitive impairment and dementia |
Q24802767 | Introducing a new section to Breast Cancer Research: Endocrinology and hormone therapy |
Q35579234 | Investigational drugs for the treatment of AD: what can we learn from negative trials? |
Q48614782 | Involvement of Luteinizing Hormone in Alzheimer Disease Development in Elderly Women |
Q81002469 | Is the WHI relevant to HRT started in the perimenopause? |
Q37018510 | Is timing everything? New insights into why the effect of estrogen therapy on memory might be age dependent |
Q36238850 | Labisia pumila Prevents Complications of Osteoporosis by Increasing Bone Strength in a Rat Model of Postmenopausal Osteoporosis |
Q34978861 | Labisia pumila regulates bone-related genes expressions in postmenopausal osteoporosis model |
Q33854590 | Lack of association of acute phase response proteins with hormone levels and antidepressant medication in perimenopausal depression |
Q35095659 | Language performance in postmenopausal women with and without hormone therapy and men. |
Q36176198 | Life-long environmental enrichment differentially affects the mnemonic response to estrogen in young, middle-aged, and aged female mice. |
Q46583975 | Lifecourse social conditions and racial and ethnic patterns of cognitive aging |
Q36375568 | Lifestyle Activities in Sociodemographically at-risk Urban, Older Adults Prior to Participation in the Baltimore Experience Corps(®) Trial |
Q90716417 | Lifetime estrogen exposure and cognition in late life: the Cache County Study |
Q35637145 | Ligand-modified aminobisphosphonate for linking proteins to hydroxyapatite and bone surface. |
Q35748577 | Lipocalin-type prostaglandin D synthase/beta-trace is a major amyloid beta-chaperone in human cerebrospinal fluid. |
Q24647962 | Liquiritigenin is a plant-derived highly selective estrogen receptor beta agonist |
Q24201974 | Long term hormone therapy for perimenopausal and postmenopausal women |
Q24241279 | Long term hormone therapy for perimenopausal and postmenopausal women |
Q24246577 | Long term hormone therapy for perimenopausal and postmenopausal women |
Q35616166 | Long-term consequences of estrogens administered in midlife on female cognitive aging |
Q37277562 | Long-term effects of bilateral oophorectomy on brain aging: unanswered questions from the Mayo Clinic Cohort Study of Oophorectomy and Aging |
Q34048789 | Long-term effects of conjugated equine estrogen therapies on domain-specific cognitive function: results from the Women's Health Initiative study of cognitive aging extension |
Q36672688 | Long-term estrogen deprivation leads to elevation of Dickkopf-1 and dysregulation of Wnt/β-Catenin signaling in hippocampal CA1 neurons |
Q30238978 | Long-term hormone therapy for perimenopausal and postmenopausal women |
Q35718091 | Long-term replacement of estrogen in combination with medroxyprogesterone acetate improves acquisition of an alternation task in middle-aged female rats |
Q38041758 | Long-term use of standardised Ginkgo biloba extract for the prevention of Alzheimer's disease (GuidAge): a randomised placebo-controlled trial |
Q41102759 | Long-term use of tamoxifen reduces the risk of dementia: a nationwide population-based cohort study |
Q37000444 | Longitudinal Cognitive Trajectories of Women Veterans from the Women's Health Initiative Memory Study |
Q92648681 | Low-fat dietary pattern and global cognitive function: Exploratory analyses of the Women's Health Initiative (WHI) randomized Dietary Modification trial |
Q57492371 | Luteinizing Hormone Involvement in Aging Female Cognition: Not All Is Estrogen Loss |
Q38510860 | Luteinizing hormone as a key player in the cognitive decline of Alzheimer's disease |
Q58485914 | Maintaining cognitive health in elderly women |
Q92403062 | Making DEEP Sense of Lifestyle Risk and Resilience |
Q39027923 | Management of Depression in Patients with Dementia: Is Pharmacological Treatment Justified? |
Q37477055 | Management of patients with mild cognitive impairment and mild to moderate dementia |
Q88676389 | Managing Menopause by Combining Evidence With Clinical Judgment |
Q35742248 | Managing the menopause. |
Q37245953 | Mechanisms enforcing the estrogen receptor β selectivity of botanical estrogens |
Q33436267 | Mechanisms of action of estrogen in the brain: insights from human neuroimaging and psychopharmacologic studies |
Q38061846 | Mechanisms underlying the dualistic mode of action of major soy isoflavones in relation to cell proliferation and cancer risks. |
Q37048086 | Medical management of frontotemporal dementia |
Q22242806 | Medications and Diet |
Q92132021 | Medroxyprogesterone Acetate Impairs Amyloid Beta Degradation in a Matrix Metalloproteinase-9 Dependent Manner |
Q35168390 | Medroxyprogesterone acetate antagonizes estrogen up-regulation of brain mitochondrial function |
Q30465714 | Medroxyprogesterone acetate impairs memory and alters the GABAergic system in aged surgically menopausal rats. |
Q43169451 | Melatonin modulates hippocampus NMDA receptors, blood and brain oxidative stress levels in ovariectomized rats |
Q38471641 | Membrane-initiated signaling of estrogen related to neuroprotection. "Social networks" are required |
Q40045531 | Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality: The Women's Health Initiative Randomized Trials |
Q36152764 | Menopausal hormone therapy |
Q76318144 | Menopausal hormone therapy after breast cancer |
Q37658616 | Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials |
Q44200265 | Menopausal hormone therapy for cardiovascular protection--unfulfilled expectations |
Q79227448 | Menopausal hormone therapy informed consent |
Q33644735 | Menopausal hormone therapy: a systematic review of cost-effectiveness evaluations |
Q36078563 | Menopausal hormone therapy: is there evidence for cardiac protection?. |
Q48441036 | Menopausal symptom perception and severity: results from a screening questionnaire |
Q37822795 | Menopause and mental well-being: timing of symptoms and timing of hormone treatment |
Q43028519 | Menopause and mitochondria: windows into estrogen effects on Alzheimer's disease risk and therapy |
Q37144896 | Menopause, estrogen, and gonadotropins in Alzheimer's disease |
Q21131065 | Menopause, obesity and inflammation: interactive risk factors for Alzheimer's disease |
Q37030684 | Menopause: developing a rational treatment plan |
Q40238961 | Meta-analyses of the effect of hormone treatment on cognitive function in postmenopausal women. |
Q36302335 | Metabolic and Non-Cognitive Manifestations of Alzheimer's Disease: The Hypothalamus as Both Culprit and Target of Pathology |
Q26994975 | Mild cognitive impairment and dementia: the importance of modifiable risk factors |
Q35194758 | Mild cognitive impairment clinical trials |
Q37047850 | Mild cognitive impairment prevention: diet, sports and treatment approaches. |
Q36036755 | Mnemonic effects of progesterone to mice require formation of 3alpha,5alpha-THP. |
Q34496551 | Modeling hot flushes and quality of life in breast cancer survivors |
Q28392016 | Modeling menopause: The utility of rodents in translational behavioral endocrinology research |
Q37436616 | Modifiable Midlife Risk Factors for Late-Life Cognitive Impairment and Dementia |
Q40006640 | Morphine protects against intracellular amyloid toxicity by inducing estradiol release and upregulation of Hsp70. |
Q36756290 | Multiple clinically relevant hormone therapy regimens fail to improve cognitive function in aged ovariectomized rhesus monkeys |
Q37502104 | Multiple hormonal dysregulation as determinant of low physical performance and mobility in older persons. |
Q36511912 | Multiple pathways transmit neuroprotective effects of gonadal steroids |
Q35206981 | NSAIDs and Alzheimer's disease: how far to generalise from trials? |
Q33242024 | Natural health products in the prevention and treatment of osteoporosis: systematic review of randomized controlled trials |
Q43227534 | Natural hormone therapy for menopause |
Q36817040 | Neuropathology and treatment of Alzheimer disease: did we lose the forest for the trees? |
Q38005895 | Neuroprotection and estrogen receptors |
Q37479919 | Neuroprotective actions of selective estrogen receptor modulators. |
Q33762953 | Neuroprotective effects of estrogen therapy for cognitive and neurobiological profiles of monkey models of menopause |
Q38530418 | Neuroprotective effects of estrogens: the role of cholesterol |
Q48298260 | Neuroscience: it's all in the timing |
Q35078498 | Neuroscientists as cartographers: mapping the crossroads of gonadal hormones, memory and age using animal models |
Q57817974 | Neurosteroid Metabolites of Gonadal Steroid Hormones in Neuroprotection: Implications for Sex Differences in Neurodegenerative Disease |
Q35971833 | Neurosteroids and GABA-A Receptor Function |
Q90077292 | Neurosteroids as regulators of neuroinflammation |
Q24618586 | Neurosteroids' effects and mechanisms for social, cognitive, emotional, and physical functions |
Q48878246 | Neurotherapeutic Effects of Pueraria mirifica Extract in Early- and Late-Stage Cognitive Impaired Rats |
Q36102771 | Neurotrophic and neuroprotective actions of estrogen: basic mechanisms and clinical implications |
Q35948672 | New HRT options for the treatment of menopausal symptoms and the maintenance of quality of life in postmenopausal women |
Q38027193 | New generation nonhormonal management for hot flashes |
Q36939490 | New hormonal therapies and regimens in the postmenopause: routes of administration and timing of initiation |
Q37436652 | New insights on the neuroprotective role of sterols and sex steroids: the seladin-1/DHCR24 paradigm |
Q34551983 | New progestogens: a review of their effects in perimenopausal and postmenopausal women |
Q46407690 | New thoughts about estrogen therapy from the Women's Health Initiative |
Q31070019 | No Association between Dietary Patterns and Risk for Cognitive Decline in Older Women with 9-Year Follow-Up: Data from the Women's Health Initiative Memory Study |
Q45239413 | No changes in event-related potentials with estrogen or estrogen plus progesterone treatment in healthy older hysterectomized women: results from a double-blind, placebo-controlled study |
Q24246936 | Non-hormonal therapy for hot flushes in postmenopausal women |
Q57341506 | Nonestrogen-based hormonal therapies for Alzheimer’s disease |
Q34411638 | Normal genetic variation, cognition, and aging |
Q36459049 | Novel mechanisms for estrogen-induced neuroprotection |
Q35579936 | Nutritional Approaches to Late Toxicities of Adjuvant Chemotherapy in Breast Cancer Survivors |
Q33694232 | Oestradiol modulation of cognition in adult female marmosets (Callithrix jacchus). |
Q37285879 | Oestrogen receptor alpha localisation in the prefrontal cortex of three mammalian species |
Q35882885 | Oestrogen signalling and neuroprotection in cerebral ischaemia |
Q33677382 | Omega-3 fatty acids and cognitive function in women |
Q40519882 | On the horizon: pathways for drug development in Alzheimer's disease |
Q44591310 | Onset of estrogen replacement has a critical effect on synaptic density of CA1 hippocampus in ovariectomized adult rats |
Q26853730 | Oophorectomy, estrogen, and dementia: a 2014 update |
Q34612492 | Oophorectomy, menopause, estrogen treatment, and cognitive aging: clinical evidence for a window of opportunity |
Q33808780 | Oophorectomy, menopause, estrogen, and cognitive aging: the timing hypothesis |
Q38169998 | Oral contraceptives and nicotine synergistically exacerbate cerebral ischemic injury in the female brain |
Q60954733 | Ovarian Cycle Stages Modulate Alzheimer-Related Cognitive and Brain Network Alterations in Female Mice |
Q35235439 | Ovarian hormone loss induces bioenergetic deficits and mitochondrial β-amyloid |
Q58738244 | Ovarian survival after pelvic radiation: transposition until the age of 35 years |
Q37244609 | Ovariectomy and 17beta-estradiol replacement do not alter beta-amyloid levels in sheep brain |
Q46511765 | Ovariectomy enhances acetylcholinesterase activity but does not alter ganglioside content in cerebral cortex of female adult rats. |
Q46467674 | Ovariectomy impairs spatial memory: prevention and reversal by a soy isoflavone diet. |
Q35643128 | Perceived control and hot flashes in treatment-seeking breast cancer survivors and menopausal women |
Q33206403 | Perimenopausal and Postmenopausal Health |
Q38218301 | Periodic Estrogen Receptor-Beta Activation: A Novel Approach to Prevent Ischemic Brain Damage |
Q37198579 | Pharmacological Treatment of Alzheimer's Disease: Is it Progressing Adequately? |
Q35957574 | Pharmacotherapeutic approaches to the prevention of Alzheimer's disease |
Q47562258 | Population Neuroscience: Dementia Epidemiology Serving Precision Medicine and Population Health |
Q43154107 | Post hoc magnetic resonance imaging cannot justify the conclusions of WHIMS. |
Q42840295 | Postmenopausal hormone therapy |
Q37742148 | Postmenopausal hormone therapy and Alzheimer disease: A prospective cohort study |
Q27008086 | Postmenopausal hormone therapy and cognition |
Q33516441 | Postmenopausal hormone therapy and cognitive outcomes: the Women's Health Initiative Memory Study (WHIMS). |
Q37180441 | Postmenopausal hormone therapy and regional brain volumes: the WHIMS-MRI Study |
Q37180460 | Postmenopausal hormone therapy and subclinical cerebrovascular disease: the WHIMS-MRI Study |
Q34420014 | Postmenopausal hormone therapy and the risks of coronary heart disease, breast cancer, and stroke |
Q37416371 | Postmenopausal hormone therapy is not associated with risk of all-cause dementia and Alzheimer's disease |
Q36355137 | Postmenopausal hormone therapy, timing of initiation, APOE and cognitive decline |
Q35692889 | Postmenopausal hormone therapy: a concise guide to therapeutic uses, formulations, risks, and alternatives |
Q30451123 | Postmenopausal hormone therapy: an Endocrine Society scientific statement. |
Q35732023 | Postmenopausal hormone therapy: impact on menopause-related symptoms, chronic disease and quality of life |
Q53350994 | Postmenopausal hormone therapy: the pros and cons. |
Q26795412 | Postmenopausal syndrome |
Q35538824 | Potential Use of Estrogen-Like Drugs for the Prevention of Alzheimer's Disease |
Q34720369 | Potential mechanisms of estrogen quinone carcinogenesis |
Q37418919 | Potential role of estrogen in the pathobiology and prevention of Alzheimer's disease. |
Q34312062 | Predicting Alzheimer's disease in the Baltimore longitudinal study of aging |
Q43673343 | Pregnancy history and cognition during and after pregnancy. |
Q37417828 | Premarin improves memory, prevents scopolamine-induced amnesia and increases number of basal forebrain choline acetyltransferase positive cells in middle-aged surgically menopausal rats |
Q33278956 | Premature ovarian failure: a review |
Q27022920 | Prescribing menopausal hormone therapy: an evidence-based approach |
Q36876447 | Present and prospective clinical therapeutic regimens for Alzheimer's disease |
Q51984926 | Prevalence of memory loss complaints and other symptoms associated with the menopause transition: a community survey. |
Q34847609 | Preventing Alzheimer's disease : separating fact from fiction |
Q37001410 | Preventing cognitive decline in healthy older adults |
Q38719665 | Prevention Trials in Alzheimer's Disease: Current Status and Future Perspectives |
Q22248031 | Prevention of Alzheimer's disease |
Q53499870 | Prevention of Alzheimer's disease, cerebrovascular disease and dementia in women: the case for menopause hormone therapy. |
Q38223587 | Prevention of diseases after menopause. |
Q38554910 | Prevention of sporadic Alzheimer's disease: lessons learned from clinical trials and future directions |
Q38983318 | Prevention studies in Alzheimer's disease: progress towards the development of new therapeutics |
Q36616443 | Prevention, Rehabilitation, and Mitigation Strategies of Cognitive Deficits in Aging with HIV: Implications for Practice and Research |
Q37670673 | Primary and Secondary Prevention Trials in Alzheimer Disease: Looking Back, Moving Forward |
Q36806653 | Primary prevention and delay of onset of AD/dementia |
Q44336092 | Progesterone and estrogen regulate Alzheimer-like neuropathology in female 3xTg-AD mice. |
Q48171447 | Progesterone enhances transthyretin expression in the rat choroid plexus in vitro and in vivo via progesterone receptor |
Q37072797 | Progesterone influence on neurite outgrowth involves microglia. |
Q37220808 | Progesterone reduces depression-like behavior in a murine model of Alzheimer's Disease |
Q30053198 | Progestin negatively affects hearing in aged women |
Q39943537 | Progestogens influence cognitive processes in aging |
Q34317537 | Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects |
Q37175385 | Progestogens' effects and mechanisms for object recognition memory across the lifespan |
Q36436653 | Prognostic factors in paediatric anaplastic large cell lymphoma: role of ALK. |
Q33772525 | Promotion of cognitive health through cognitive activity in the aging population |
Q35119064 | Prospective randomized trial to assess effects of continuing hormone therapy on cerebral function in postmenopausal women at risk for dementia |
Q37309638 | Protective actions of sex steroid hormones in Alzheimer's disease |
Q36972735 | Protein phosphatase 1, protein phosphatase 2A, and calcineurin play a role in estrogen-mediated neuroprotection |
Q37261100 | Provider attributes associated with hormone therapy prescribing frequency |
Q47420424 | Pueraria lobate Inhibits RANKL-Mediated Osteoclastogenesis Via Downregulation of CREB/PGC1β/c-Fos/NFATc1 Signaling |
Q35707934 | Quinoids formed from estrogens and antiestrogens |
Q37063691 | Rationale and design of the Kronos Early Estrogen Prevention Study (KEEPS) and the KEEPS Cognitive and Affective sub study (KEEPS Cog) |
Q22242395 | Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline |
Q38002365 | Recruitment methods for United States Alzheimer disease prevention trials |
Q34604092 | Reducing case ascertainment costs in U.S. population studies of Alzheimer's disease, dementia, and cognitive impairment-Part 1 |
Q28583938 | Regulation of Cytokine-Induced Neuron Death by Ovarian Hormones: Involvement of Antiapoptotic Protein Expression and c-JUN N-Terminal Kinase-Mediated Proapoptotic Signaling |
Q48922535 | Regulation of synaptic plasticity by hippocampus synthesized estradiol |
Q36691761 | Relationship between estrogen and schizophrenia |
Q54308569 | Relationship between the neuroprotective effects of insulin-like growth factor-1 and 17β-oestradiol in human neuroblasts. |
Q33831158 | Relationship of hypertension, blood pressure, and blood pressure control with white matter abnormalities in the Women's Health Initiative Memory Study (WHIMS)-MRI trial |
Q39767296 | Reorganization of Functional Networks in Verbal Working Memory Circuitry in Early Midlife: The Impact of Sex and Menopausal Status |
Q51533934 | Reporting on post-menopausal hormone therapy: an analysis of gynaecologists' web pages. |
Q30451655 | Reproductive aging, menopause, and health outcomes |
Q33820067 | Reproductive aging, sex steroids, and mood disorders |
Q89951553 | Reproductive and hormonal factors and risk of cognitive impairment among Singapore Chinese women |
Q36328001 | Response to dr simes and dr snabes |
Q56031122 | Review of the effects of 17α-estradiol in humans: a less feminizing estrogen with neuroprotective potential |
Q28262783 | Risk factors for dementia |
Q24647700 | Role of androgens, progestins and tibolone in the treatment of menopausal symptoms: a review of the clinical evidence |
Q36019567 | Role of progestins with partial antiandrogenic effects |
Q46633788 | Role of protein phosphatases in estrogen-mediated neuroprotection. |
Q24625569 | Roles for oestrogen receptor β in adult brain function |
Q64063020 | Royal Jelly Ameliorates Behavioral Deficits, Cholinergic System Deficiency, and Autonomic Nervous Dysfunction in Ovariectomized Cholesterol-Fed Rabbits |
Q36794420 | SERMs for the treatment and prevention of breast cancer |
Q38700757 | Safety and benefit considerations for menopausal hormone therapy |
Q34362281 | Scientific rationale for postmenopause delay in the use of conjugated equine estrogens among postmenopausal women that causes reduction in breast cancer incidence and mortality |
Q33236269 | Select estrogens within the complex formulation of conjugated equine estrogens (Premarin) are protective against neurodegenerative insults: implications for a composition of estrogen therapy to promote neuronal function and prevent Alzheimer's disea |
Q35721863 | Selective estrogen receptor modulation: concept and consequences in cancer |
Q35569533 | Selective estrogen receptor modulators (SERMs) enhance neurogenesis and spine density following focal cerebral ischemia |
Q38808173 | Serum SHBG Levels are not Associated with Longitudinal Cognitive Decline in Mild Cognitive Impairment |
Q40281627 | Serum phosphate and cognitive function in older men. |
Q47836220 | Sex Hormones and Healthy Psychological Aging in Women. |
Q91706991 | Sex and Gender Driven Modifiers of Alzheimer's: The Role for Estrogenic Control Across Age, Race, Medical, and Lifestyle Risks |
Q34214272 | Sex and gender differences in the causes of dementia: a narrative review |
Q36473640 | Sex and gonadal hormones in mouse models of Alzheimer's disease: what is relevant to the human condition? |
Q50506777 | Sex and post-menopause hormone therapy effects on hippocampal volume and verbal memory. |
Q37432182 | Sex and the development of Alzheimer's disease. |
Q48617816 | Sex differences in Alzheimer's disease risk: are we looking at the wrong hormones? |
Q33864547 | Sex differences in cognitive impairment and Alzheimer's disease |
Q82035418 | Sex differences in stroke |
Q35103802 | Sex hormones affect neurotransmitters and shape the adult female brain during hormonal transition periods |
Q46221971 | Sex steroid hormones and brain function: PET imaging as a tool for research |
Q38119012 | Sex, hormones and neurogenesis in the hippocampus: hormonal modulation of neurogenesis and potential functional implications |
Q36176965 | Sex, hormones, and Alzheimer's disease |
Q49601287 | Sex-related differences in oxidative stress and neurodegeneration |
Q64089258 | Sexual Function and Factors Affecting Menopause: A Systematic Review |
Q35083240 | Sexual dimorphism in ischemic stroke: lessons from the laboratory |
Q57143986 | Sexual dimorphism in predisposition to Alzheimer's disease |
Q35015991 | Sharing clinical decisions by discussing evidence with patients |
Q46342146 | Short-term effects of treatment-induced hormonal changes on cognitive function in breast cancer patients: results of a multicenter, prospective, longitudinal study |
Q36024730 | Single and multiple ascending dose studies of a novel tissue-selective oestrogen receptor modulator, CHF 4227, in healthy postmenopausal women |
Q33267870 | Skin and menopause |
Q36373516 | Sleep duration, cognitive decline, and dementia risk in older women |
Q44799141 | Spatial memory retention is enhanced by acute and continuous estradiol replacement |
Q36084087 | Standards of Evidence for Efficacy, Effectiveness, and Scale-up Research in Prevention Science: Next Generation |
Q40363847 | Standards of evidence: criteria for efficacy, effectiveness and dissemination |
Q24603957 | Statin adverse effects : a review of the literature and evidence for a mitochondrial mechanism |
Q46011754 | Statin-associated adverse cognitive effects: survey results from 171 patients. |
Q55333269 | Steroid Hormones and Their Action in Women's Brains: The Importance of Hormonal Balance. |
Q35070362 | Steroidogenic acute regulatory protein (StAR): evidence of gonadotropin-induced steroidogenesis in Alzheimer disease |
Q39432214 | Strategies for Preventing Cognitive Decline in Healthy Older Adults |
Q37714345 | Stroke in women |
Q35867501 | Structure-nongenomic neuroprotection relationship of estrogens and estrogen-derived compounds |
Q33462283 | Subcortical ischemic cerebrovascular dementia |
Q34088579 | Subtypes of mild cognitive impairment in older postmenopausal women: the Women's Health Initiative Memory Study |
Q43424580 | Sugary foods and gynecological cancer risk |
Q35765716 | Symptomatic and nonamyloid/tau based pharmacologic treatment for Alzheimer disease |
Q58582917 | Synaptic distributions of pS214-tau in rhesus monkey prefrontal cortex are associated with spine density, but not with cognitive decline |
Q38840921 | Targeting MicroRNAs Involved in the BDNF Signaling Impairment in Neurodegenerative Diseases. |
Q35016901 | Targeting gonadotropins: an alternative option for Alzheimer disease treatment |
Q44852721 | Testosterone and the brain: uncharted territory |
Q24248598 | Testosterone for peri- and postmenopausal women |
Q34161400 | The 2012 hormone therapy position statement of: The North American Menopause Society |
Q58614226 | The Association Between Body Mass Index, and Cognitive, Functional, and Behavioral Declines for Incident Dementia |
Q33873941 | The Cache County Study on Memory in Aging: factors affecting risk of Alzheimer's disease and its progression after onset |
Q90637954 | The Effect of Estrogen Replacement Therapy on Alzheimer's Disease and Parkinson's Disease in Postmenopausal Women: A Meta-Analysis |
Q33716695 | The Effect of Luteinizing Hormone Reducing Agent on Anxiety and Novel Object Recognition Memory in Gonadectomized Rats |
Q35952978 | The GABAA antagonist bicuculline attenuates progesterone-induced memory impairments in middle-aged ovariectomized rats |
Q57054214 | The Middle-Aged Brain: Biological sex and sex hormones shape memory circuitry |
Q38927944 | The Potential of Gonadal Hormone Signalling Pathways as Therapeutics for Dementia. |
Q91262891 | The TOMMORROW study: Design of an Alzheimer's disease delay-of-onset clinical trial |
Q35234851 | The TU-025 keishibukuryogan clinical trial for hot flash management in postmenopausal women: results and lessons for future research |
Q38602074 | The Utility of the Cognitive Function Instrument (CFI) to Detect Cognitive Decline in Non-Demented Older Adults. |
Q46797789 | The Women's Health Initiative Study of Cognitive Aging (WHISCA): a randomized clinical trial of the effects of hormone therapy on age-associated cognitive decline |
Q36103525 | The Women's Health Initiative study: perspectives and implications for clinical practice |
Q36668062 | The ageing cortical synapse: hallmarks and implications for cognitive decline |
Q35444823 | The allelic modulation of apolipoprotein E expression by oestrogen: potential relevance for Alzheimer's disease |
Q40190946 | The association between an inflammatory diet and global cognitive function and incident dementia in older women: The Women's Health Initiative Memory Study. |
Q88636986 | The borderland between normal aging and dementia |
Q22299214 | The breast cancer epidemic: 10 facts |
Q30496612 | The cognitive effects of conjugated equine estrogens depend on whether menopause etiology is transitional or surgical |
Q36203397 | The contribution of luteinizing hormone to Alzheimer disease pathogenesis |
Q36704008 | The critical period hypothesis: can it explain discrepancies in the oestrogen-cognition literature? |
Q34200495 | The cross-sectional relationship between body mass index, waist-hip ratio, and cognitive performance in postmenopausal women enrolled in the Women's Health Initiative |
Q36094647 | The current state of postmenopausal hormone therapy: update for neurologists and epileptologists |
Q37244686 | The differences in neuroprotective efficacy of progesterone and medroxyprogesterone acetate correlate with their effects on brain-derived neurotrophic factor expression |
Q37361099 | The effect of gonadectomy and estradiol on sensitivity to oxidative stress. |
Q37172024 | The effects of acute 17beta-estradiol treatment on gene expression in the young female mouse hippocampus. |
Q48130002 | The effects of chronic estradiol treatment on working memory deficits induced by combined infusion of beta-amyloid (1-42) and ibotenic acid |
Q36439357 | The effects of long-term treatment with estradiol and medroxyprogesterone acetate on tyrosine hydroxylase fibers and neuron number in the medial prefrontal cortex of aged female rats. |
Q37975168 | The hormonal pathway to cognitive impairment in older men. |
Q34722892 | The impact of comorbidities on hormone use. After the 2000 release of the Women's Health Initiative |
Q57467639 | The lifespan Human Connectome Project in aging: An overview |
Q36710473 | The medical management of menopause: a four-country comparison care in urban areas |
Q53282854 | The number of pregnancies is a risk factor for Alzheimer's disease. |
Q28263673 | The potential for estrogens in preventing Alzheimer's disease and vascular dementia |
Q37725622 | The pregnane xenobiotic receptor, a prominent liver factor, has actions in the midbrain for neurosteroid synthesis and behavioral/neural plasticity of female rats |
Q82715303 | The prevention of dementia |
Q25257485 | The progestational and androgenic properties of medroxyprogesterone acetate: gene regulatory overlap with dihydrotestosterone in breast cancer cells |
Q36933312 | The rationale, design, and baseline characteristics of the Women's Health Initiative Memory Study of Younger Women (WHIMS-Y). |
Q33290019 | The role of adolescent IQ and gender in the use of cognitive support for remembering in aging |
Q36511930 | The role of gonadotropins in Alzheimer's disease: potential neurodegenerative mechanisms. |
Q37145381 | The role of hormone therapy and calcium plus vitamin D for reduction of bone loss and risk for fractures: lessons learned from the Women's Health Initiative |
Q61799790 | The role of hydrogen in Alzheimer's disease |
Q36577266 | Therapy Insight: type 2 diabetes mellitus and the risk of late-onset Alzheimer's disease |
Q57341342 | Thinking Outside the Box in Alzheimer Disease Treatment |
Q35544502 | Thinking globally, acting locally: steroid hormone regulation of the dendritic architecture, synaptic connectivity and death of an individual neuron |
Q34536301 | Three midlife strategies to prevent cognitive impairment due to Alzheimer's disease |
Q37223038 | Thyroid function and the risk of Alzheimer disease: the Framingham Study |
Q35191452 | Time and dose-dependent effects of Labisia pumila on the bone strength of postmenopausal osteoporosis rat model. |
Q89308533 | Timing of cyclic estradiol treatment differentially affects cognition in aged female rhesus monkeys |
Q34683673 | Timing of hormone therapy and dementia: the critical window theory revisited |
Q34468841 | Tonic Premarin dose-dependently enhances memory, affects neurotrophin protein levels and alters gene expression in middle-aged rats. |
Q28600847 | Trajectories and phenotypes with estrogen exposures across the lifespan: What does Goldilocks have to do with it? |
Q34684381 | Translational research on the way to effective therapy for Alzheimer disease |
Q36388561 | Treating vascular risk factors and maintaining vascular health: is this the way towards successful cognitive ageing and preventing cognitive decline? |
Q47148252 | Treatment of Alzheimer's disease in Brazil: I. Cognitive disorders |
Q36219667 | Treatment of menopausal symptoms post-Women's Health Initiative: refinement of existing treatments and development of new therapies |
Q36213129 | Treatment of menopausal symptoms: what shall we do now? |
Q35068765 | Trends in menopausal hormone therapy use of US office-based physicians, 2000-2009 |
Q36737783 | Uncovering the mechanisms of estrogen effects on hippocampal function. |
Q89119354 | Understanding the impact of sex and gender in Alzheimer's disease: A call to action |
Q51044084 | Underuse of ovarian transposition in reproductive-aged cancer patients treated by primary or adjuvant pelvic irradiation. |
Q35941842 | Update on the effect of estradiol in postmenopause women with Alzheimer's disease: a systematic review |
Q37989179 | Update: estrogen and estrogen plus progestin therapy in the care of women at and after the menopause |
Q46064533 | Use of compounded bioidentical hormone therapy in menopausal women: an opinion statement of the Women's Health Practice and Research Network of the American College of Clinical Pharmacy |
Q36149372 | Use of hormone replacement therapy by postmenopausal women after publication of the Women's Health Initiative Trial |
Q64055802 | Use of postmenopausal hormone therapy and risk of Alzheimer’s disease in Finland: nationwide case-control study |
Q30513312 | Using predictors of hormone therapy use to model the healthy user bias: how does healthy user status influence cognitive effects of hormone therapy? |
Q53365863 | Variations in estrogen receptor alpha gene and risk of dementia, and brain volumes on MRI. |
Q36331030 | Vascular dementia prevention: a risk factor analysis |
Q34659256 | Vascular dementia: a review of recent evidence for prevention and treatment |
Q37299896 | Vascular factors and prevention of dementia. |
Q35636070 | Verbal episodic memory and endogenous estradiol: an association in patients with mild cognitive impairment and Alzheimer's disease |
Q33782547 | Vitamin D insufficiency. |
Q50736681 | Web chatter before and after the Women's Health Initiative results: a content analysis of on-line menopause message boards. |
Q40418625 | Weight Trajectory over 20 Years and Likelihood of Mild Cognitive Impairment or Dementia Among Older Women |
Q38034060 | What have we learned from the streptozotocin-induced animal model of sporadic Alzheimer's disease, about the therapeutic strategies in Alzheimer's research |
Q44969204 | What is the rationale for new treatment strategies in Alzheimer's disease? |
Q27021193 | When Mars Versus Venus is Not a Cliché: Gender Differences in the Neurobiology of Alzheimer's Disease |
Q53220661 | When practices, promises, profits, and policies outpace hard evidence: the post-menopausal hormone debate. |
Q36350786 | Where are we with postmenopausal hormone therapy in 2005? |
Q38796711 | Why estrogens matter for behavior and brain health |
Q37252601 | Women with and without intellectual disability and psychiatric disorders: an examination of the literature |
Q57055214 | Women's Health Initiative: Statistical Aspects and Selected Early Results |
Q57055349 | Women's Health Initiative: Statistical Aspects and Selected Early Results |
Q52000029 | Women's cognitive health: postmenopausal dementia and the women's health initiative memory study. |
Q48411484 | Women's conception of the menopausal transition--a qualitative study |
Q79299218 | Women's health issues |
Q80329306 | [AFSSAPS recommendations about menopause] |
Q80589015 | [Evidence based basis of decision making for or against a postmenopausal hormone treatment] |
Q75198766 | [Hormone therapy in menopause. A current update] |
Q39329106 | [Menopausal hormone therapy]. |
Q53282559 | [New therapeutic approaches in Alzheimer disease]. |
Q80252373 | [Risk factors for Alzheimer: towards prevention?] |
Q81420397 | [Role of hormone-replacement therapy for prevention of coronary artery disease in women] |
Q79780869 | [Should the menopause be treated?] |
Q83950697 | [Should we change our attitude on postmenopausal hormone replacement therapy?] |
Q81591791 | [Update on menopause treatments, after recent controversies] |
Search more.